Oruka Q2 Net Loss Expands; Expects Phase 2 EVERLAST-A 28 Week Data Of ORKA-001 At The End Of Q3 2026
Oruka Therapeutics (ORKA) reported Q2 2026 net loss of $41.21 million, up from $24.57 million a year earlier. The company said it had $1.1 billion in cash, cash equivalents and marketable securities as of June 30, 2026. Phase 2 EVERLAST-A 28-week data for ORKA-001 is expected end of Q3 2026, with 52-week data in Dec 2026.
How this was made
The 30-second read
Why it matters
Traders can use the Q2 net loss expansion and the reiterated, time-specific Phase 2 milestones to frame event-driven risk into late Q3 2026 (EVERLAST-A 28-week) and Q4 2026 (EVERLAST-B 16-week).
Market read
Company-specific financial deterioration is paired with concrete upcoming clinical catalysts and a cash runway statement, creating a tradable event calendar for ORKA.
What to watch
The article does not quantify trial efficacy or safety outcomes, so the market may focus more on future data quality than on the financial loss figure.
Background
Oruka Therapeutics is a clinical-stage biotech focused on chronic skin diseases, with lead Phase 2 programs ORKA-001 (IL-23p19) and ORKA-002 (IL-17A/F).
Ticker impact
Oruka reported Q2 2026 net loss of $41.21M and guided Phase 2 EVERLAST-A 28-week data to end of Q3 2026.
Likely choppy to downside-biased until the next Phase 2 data milestones, with volatility around Q3 2026 and Q4 2026 readout windows.
The article provides a fresh financial datapoint (net loss expansion) and time-stamped clinical catalysts (EVERLAST-A 28-week end-Q3 2026; EVERLAST-B 16-week Q4 2026) plus a cash runway statement through an anticipated BLA filing for ORKA-001.
Market effects
Adds another IL-23/IL-17 psoriasis-biologics development timeline datapoint that can influence sentiment for clinical-stage dermatology peers.
No clear regional macro linkage beyond general US biotech risk appetite.
Limited, as the update is company-specific and not tied to a global regulatory or market-wide event.
Counterpoint
The cash balance ($1.1B) and planned BLA path may offset the net loss expansion, supporting a longer-duration hold into upcoming Phase 2 readouts.
Key entities
- companyOruka Therapeutics, Inc.
Clinical-stage biotech reporting Q2 2026 results and updating Phase 2 timelines for ORKA-001 and ORKA-002.
- programORKA-001
Phase 2 monoclonal antibody targeting IL-23p19; EVERLAST-A 28-week data expected end of Q3 2026.
- programORKA-002
Phase 2 monoclonal antibody targeting IL-17A/F; ORCA-SURGE week 16 data expected in Q1 2027.
- trialEVERLAST-A
Phase 2 trial for ORKA-001 in psoriasis; 28-week data expected end of Q3 2026.
- trialEVERLAST-B
Phase 2b dose-ranging trial for ORKA-001 in moderate-to-severe psoriasis; 16-week data expected in Q4 2026.
